Lv537
1578 积分 2025-07-27 加入
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
2小时前
已完结
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2小时前
已完结
The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)
1天前
已完结
The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC)
2天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2天前
已完结
From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC
4天前
已完结
KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms
4天前
已完结
腹膜假黏液瘤诊疗中国专家共识（2026年版）
9天前
已完结
Ultrasound Criteria of Malignancy for Cervical Lymph Nodes in Patients Followed Up for Differentiated Thyroid Cancer
9天前
已完结
皖公网安备34019202002308
